• Je něco špatně v tomto záznamu ?

Evidence from routine clinical practice: EMPRISE provides a new perspective on CVOTs

G. Schernthaner, A. Karasik, A. Abraitienė, AS. Ametov, Z. Gaàl, J. Gumprecht, A. Janež, S. Kaser, K. Lalić, BN. Mankovsky, E. Moshkovich, M. Past, M. Prázný, G. Radulian, L. Smirčić Duvnjak, I. Tkáč, K. Trušinskis,

. 2019 ; 18 (1) : 115. [pub] 20190831

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20023730

EMPA-REG OUTCOME is recognised by international guidelines as a landmark study that showed a significant cardioprotective benefit with empagliflozin in patients with type 2 diabetes (T2D) and cardiovascular disease. To assess the impact of empagliflozin in routine clinical practice, the ongoing EMPRISE study is collecting real-world evidence to compare effectiveness, safety and health economic outcomes between empagliflozin and DPP-4 inhibitors. A planned interim analysis of EMPRISE was recently published, confirming a substantial reduction in hospitalisation for heart failure with empagliflozin across a diverse patient population. In this commentary article, we discuss the new data in the context of current evidence and clinical guidelines, as clinicians experienced in managing cardiovascular risk in patients with T2D. We also look forward to what future insights EMPRISE may offer, as evidence is accumulated over the next years to complement the important findings of EMPA-REG OUTCOME.

3rd Department of Internal Medicine 1st Faculty of Medicine Charles University Prague Prague Czech Republic

Carol Davila University of Medicine and Pharmacy Bucharest Romania

Clinic for Endocrinology Diabetes and Metabolic Diseases Clinical Centre of Serbia Faculty of Medicine University of Belgrade Belgrade Serbia

Clinic of Internal Diseases Family Medicine and Oncology Institute of Medicine Faculty of Medicine Vilnius University Hospital Santaros Klinikos Vilnius University Vilnius Lithuania

Department of Endocrinology Diabetes and Metabolic Diseases University Medical Centre Ljubljana Slovenia

Department of Internal Medicine 1 and CD Laboratory for Metabolic Crosstalk Medical University of Innsbruck Innsbruck Tirol Austria

Department of Internal Medicine 4 Faculty of Medicine Safarik University in Košice Košice Slovakia

Department of Medicine András Jósa Teaching Hospital Nyíregyháza Hungary

Diabetes and Endocrinology Clinic Clalit Medical Services Ramat Gan Israel

Estonian Diabetes Center Tallinn Estonia

Latvian Center of Cardiology Stradiņš Clinical University Hospital Rīga Stradiņš University Riga Latvia

Medical University of Silesia Katowice Poland

Medical University of Vienna Vienna Austria

National Medical Academy for Postgraduate Education Kiev Ukraine

Russian Medical Academy for Continuous Professional Education Ministry of Education of the Russian Federation Moscow Russia

School of Medicine University of Zagreb Vuk Vrhovac University Clinic UH Merkur Zagreb Croatia

Sheba Medical Center and Tel Aviv University Tel Aviv Israel

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20023730
003      
CZ-PrNML
005      
20201214131003.0
007      
ta
008      
201125s2019 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s12933-019-0920-3 $2 doi
035    __
$a (PubMed)31472683
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Schernthaner, Guntram $u Medical University of Vienna, Vienna, Austria. guntram.schernthaner@meduniwien.ac.at.
245    10
$a Evidence from routine clinical practice: EMPRISE provides a new perspective on CVOTs / $c G. Schernthaner, A. Karasik, A. Abraitienė, AS. Ametov, Z. Gaàl, J. Gumprecht, A. Janež, S. Kaser, K. Lalić, BN. Mankovsky, E. Moshkovich, M. Past, M. Prázný, G. Radulian, L. Smirčić Duvnjak, I. Tkáč, K. Trušinskis,
520    9_
$a EMPA-REG OUTCOME is recognised by international guidelines as a landmark study that showed a significant cardioprotective benefit with empagliflozin in patients with type 2 diabetes (T2D) and cardiovascular disease. To assess the impact of empagliflozin in routine clinical practice, the ongoing EMPRISE study is collecting real-world evidence to compare effectiveness, safety and health economic outcomes between empagliflozin and DPP-4 inhibitors. A planned interim analysis of EMPRISE was recently published, confirming a substantial reduction in hospitalisation for heart failure with empagliflozin across a diverse patient population. In this commentary article, we discuss the new data in the context of current evidence and clinical guidelines, as clinicians experienced in managing cardiovascular risk in patients with T2D. We also look forward to what future insights EMPRISE may offer, as evidence is accumulated over the next years to complement the important findings of EMPA-REG OUTCOME.
650    _2
$a benzhydrylové sloučeniny $x škodlivé účinky $x terapeutické užití $7 D001559
650    _2
$a kardiovaskulární nemoci $x diagnóza $x mortalita $x terapie $7 D002318
650    _2
$a klinické rozhodování $7 D000066491
650    _2
$a klinické zkoušky jako téma $x metody $7 D002986
650    _2
$a diabetes mellitus 2. typu $x diagnóza $x farmakoterapie $x mortalita $7 D003924
650    12
$a medicína založená na důkazech $7 D019317
650    _2
$a glukosidy $x škodlivé účinky $x terapeutické užití $7 D005960
650    _2
$a hospitalizace $7 D006760
650    _2
$a lidé $7 D006801
650    _2
$a směrnice pro lékařskou praxi jako téma $7 D017410
650    _2
$a lékařská praxe - způsoby provádění $7 D010818
650    _2
$a ochranné faktory $7 D065840
650    12
$a výzkumný projekt $7 D012107
650    _2
$a hodnocení rizik $7 D018570
650    _2
$a rizikové faktory $7 D012307
650    _2
$a glifloziny $x škodlivé účinky $x terapeutické užití $7 D000077203
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Karasik, Avraham $u Sheba Medical Center and Tel Aviv University, Tel Aviv, Israel. karasik@post.tau.ac.il.
700    1_
$a Abraitienė, Agnė $u Clinic of Internal Diseases, Family Medicine and Oncology, Institute of Medicine, Faculty of Medicine, Vilnius University Hospital Santaros Klinikos, Vilnius University, Vilnius, Lithuania.
700    1_
$a Ametov, Alexander S $u Russian Medical Academy for Continuous Professional Education, Ministry of Education of the Russian Federation, Moscow, Russia.
700    1_
$a Gaàl, Zsolt $u Department of Medicine, András Jósa Teaching Hospital, Nyíregyháza, Hungary.
700    1_
$a Gumprecht, Janusz $u Medical University of Silesia, Katowice, Poland.
700    1_
$a Janež, Andrej $u Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre, Ljubljana, Slovenia.
700    1_
$a Kaser, Susanne $u Department of Internal Medicine I and CD Laboratory for Metabolic Crosstalk, Medical University of Innsbruck, Innsbruck, Tirol, Austria.
700    1_
$a Lalić, Katarina $u Clinic for Endocrinology, Diabetes and Metabolic Diseases, Clinical Centre of Serbia, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.
700    1_
$a Mankovsky, Boris N $u National Medical Academy for Postgraduate Education, Kiev, Ukraine.
700    1_
$a Moshkovich, Evgeny $u Diabetes and Endocrinology Clinic, Clalit Medical Services, Ramat Gan, Israel.
700    1_
$a Past, Marju $u Estonian Diabetes Center, Tallinn, Estonia.
700    1_
$a Prázný, Martin $u 3rd Department of Internal Medicine, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Radulian, Gabriela $u Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
700    1_
$a Smirčić Duvnjak, Lea $u School of Medicine, University of Zagreb, Vuk Vrhovac University Clinic-UH Merkur, Zagreb, Croatia.
700    1_
$a Tkáč, Ivan $u Department of Internal Medicine 4, Faculty of Medicine, Safarik University in Košice, Košice, Slovakia.
700    1_
$a Trušinskis, Kārlis $u Latvian Center of Cardiology, Stradiņš Clinical University Hospital, Rīga Stradiņš University, Riga, Latvia.
773    0_
$w MED00008211 $t Cardiovascular diabetology $x 1475-2840 $g Roč. 18, č. 1 (2019), s. 115
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31472683 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201214131001 $b ABA008
999    __
$a ok $b bmc $g 1596049 $s 1114406
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 18 $c 1 $d 115 $e 20190831 $i 1475-2840 $m Cardiovascular diabetology $n Cardiovasc Diabetol $x MED00008211
LZP    __
$a Pubmed-20201125
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace